Koji Pharmaceutical: Zevoki Olun Said Research Progress at the Car-TCR annual summit display

On September 21, 2022, Koji Pharmaceutical, a Hong Kong stock company-B (02171.HK), issued an announcement that the seventh CAR-TCR held in Boston, Massachusetts

At the annual summit, the company verbally introduced Zevoki Lun Sai injection ("ZEVOR-CEL", Product Number: CT053) (a self-CAR-T candidate product for BCMA) in North America 2 clinical trials. The multi -center, open label 1B/2 stage test (NCT03915184) is undergoing the safety and effectiveness of patients with patients with multiple myeloma (R/R MM) in North America.

The test results show that Zevor-Cel's initial 17 recurrence / difficulty cure multiple osteoma at the initial test of the 2nd test shows the prospective effect and MRD negative in patients with 1.8 × 108 CAR-T cell dose. Outpatient treatment is currently being explored.

According to the announcement, ZEVOR-CEL (CT053) is an anti-autologous BCMA CAR-T cell candidate product for the treatment of recurrence / difficulty cure multi-myeloma. Koji Pharmaceutical is conducting 1B/2 clinical trials in North America to evaluate the safety and efficacy of ZEVOR-CEL for the treatment of recurrence/difficulty cure multi-mys myeloma. The company also plans to conduct other clinical trials to develop ZEVOR-CEL as a multi-line treatment method for multiple osteoma.

The company believes that ZEVOR-CEL is likely to reshape the treatment paradigm of multiple osteoma and become the basic treatment for patients with multiple myeloma.

- END -